FIELD: medicine.
SUBSTANCE: invention relates to medicine, specifically to oncology, and can be used in the treatment of epithelioid sarcoma and a malignant rhabdoid tumour. Method comprises administering to a subject in need thereof a therapeutically effective amount of an EZH2 inhibitor.
EFFECT: use of the invention allows to achieve regression of the tumour due to targeted inhibition of histone methyltransferase.
22 cl, 6 tbl, 16 dwg, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMAN EZH2 INHIBITORS AND METHODS FOR USE THEREOF | 2013 |
|
RU2704445C2 |
| METHODS FOR INCREASING STABILISATION OF HYPOXYA INDUCED FACTOR-1 ALPHA | 2010 |
|
RU2521251C2 |
| CHIRAL DIARYL MACROCYCLES AND USE THEREOF | 2016 |
|
RU2728579C2 |
| TREATING CONDITIONS ASSOCIATED WITH HYPERINSULINEMIA | 2015 |
|
RU2722179C2 |
| HDAC INHIBITORS | 2014 |
|
RU2665554C2 |
| SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | 2011 |
|
RU2606514C2 |
| SUBSTITUTED BENZENE COMPOUNDS | 2012 |
|
RU2629118C2 |
| ACTIVIN RECEPTOR-LIKE KINASE INHIBITORS | 2018 |
|
RU2788628C2 |
| SUBSTITUTED AROMATIC DERIVATIVE WITH CONDENSED RINGS AND COMPOSITION INCLUDING IT AND THEIR USE | 2020 |
|
RU2811484C1 |
| APPLICATION OF STABILISERS OF HIF- ALPHA FOR INTENSIFICATION OF ERYTHROPOIESIS | 2004 |
|
RU2414214C2 |
